aromasil has been researched along with palbociclib in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 12 (63.16) | 24.3611 |
| 2020's | 7 (36.84) | 2.80 |
| Authors | Studies |
|---|---|
| Johnston, SR | 1 |
| Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E | 1 |
| Andre, F; Bartlett, CH; Beaney, M; Bliss, JM; Cristofanilli, M; Dowsett, M; Fribbens, C; Garcia-Murillas, I; Hrebien, S; Jiang, J; Johnston, SR; Kilburn, L; Koehler, M; Loi, S; Loibl, S; O'Leary, B; Turner, NC | 1 |
| Gilarranz, YJ; Lopez-Tarruella, S; Martin, M | 1 |
| Katzenellenbogen, BS; Piccart, M; Tryfonidis, K; Zardavas, D | 1 |
| Niraula, S; Ocana, A | 1 |
| Caramia, F; Joshi, S; Loi, S; Moodie, K; Savas, P; Van Geelen, C; Wein, L | 1 |
| Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D | 1 |
| Huang, HW; Huang, LS; Li, XY; Lin, JZ; Wang, HB; Xu, QN | 1 |
| Arpino, G; Bachelot, T; Cristofanilli, M; De Laurentiis, M; De Placido, P; De Placido, S; Del Mastro, L; Generali, D; Giordano, A; Giuliano, M; Jerusalem, G; Milani, M; Pistilli, B; Prat, A; Puglisi, F; Rognoni, C; Schettini, F; Thomas, G; Venturini, S | 1 |
| Robert, M; Turner, N | 1 |
| Ahn, HK; Ahn, JS; Im, SA; Im, YH; Jung, KH; Kang, SY; Kim, GM; Kim, HJ; Kim, JH; Kim, JY; Kim, SB; Kim, TY; Koh, SJ; Lee, JI; Lee, KE; Lee, KH; Lee, MH; Park, IH; Park, YH; Sohn, J | 1 |
| Guillaume, Z; Lillo-Lelouet, A; Marret, G; Medioni, J; Oudard, S; Simonaggio, A | 1 |
| Chen, PH; Ho, CL; Huang, TC; Kang, YN; Lee, CH; Lin, C; Wu, YY | 1 |
| Coudert, B; Goirand, F; Guérard, P; Macaire, P; Schmitt, A; Vaury, C | 1 |
| Ahn, HK; Im, SA; Jung, KH; Kang, SY; Kim, GM; Kim, JH; Lee, J; Park, IH; Park, YH | 1 |
| Jeon, SY; Lee, KS; Park, IH; Sim, SH; Yang, HN | 1 |
| Alba, E; Alvarez, E; Antón, A; Bermejo, B; Calvo, L; Carrasco, E; Casas, M; Ciruelos, E; Corsaro, M; Csöszi, T; de la Haba-Rodriguez, J; Gal-Yam, E; Garcia-Palomo, A; Gil-Gil, M; González-Santiago, S; Kahan, Z; Lang, I; López, IÁ; Margeli, M; Martín, M; Morales, S; Muñoz, M; Murillo, L; Ramos, M; Rodrigálvarez, G; Rodríguez, CA; Ruiz-Borrego, M; Servitja, S; Zielinski, C | 1 |
| Goncalves, A; Mezni, E; Sabatier, R; Vicier, C | 1 |
10 review(s) available for aromasil and palbociclib
| Article | Year |
|---|---|
Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways.
Topics: Adult; Aged; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Letrozole; Middle Aged; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Research Design; Signal Transduction; Triazoles | 2015 |
Better Together: Targeted Combination Therapies in Breast Cancer.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2015 |
Endocrine therapy for hormone treatment-naïve advanced breast cancer.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Estradiol; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Tamoxifen; Triazoles | 2016 |
Endocrine treatment in breast cancer: Cure, resistance and beyond.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Molecular Targeted Therapy; Neoadjuvant Therapy; Piperazines; Pyridines; Receptors, Estrogen; Tamoxifen | 2016 |
Mechanism of drug resistance in relation to site of metastasis: Meta-analyses of randomized controlled trials in advanced breast cancer according to anticancer strategy.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease-Free Survival; Drug Resistance, Neoplasm; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Trastuzumab; Triazoles | 2016 |
Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Breast Neoplasms; Disease-Free Survival; Estradiol; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Nitriles; Piperazines; Pyridines; Randomized Controlled Trials as Topic; Triazoles | 2017 |
CDK4/6 inhibition versus mTOR blockade as second-line strategy in postmenopausal patients with hormone receptor-positive advanced breast cancer: A network meta-analysis.
Topics: Aminopyridines; Androstadienes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Breast Neoplasms; ErbB Receptors; Everolimus; Female; Fulvestrant; Humans; Network Meta-Analysis; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; TOR Serine-Threonine Kinases | 2019 |
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis.
Topics: Aminopyridines; Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Female; Fulvestrant; Humans; Letrozole; Network Meta-Analysis; Paclitaxel; Piperazines; Postmenopause; Progression-Free Survival; Purines; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone | 2019 |
Endocrine therapies in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, pretreated, advanced breast cancer: A network meta-analysis.
Topics: Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Disease-Free Survival; Everolimus; Female; Fulvestrant; Humans; Neoplasm Grading; Network Meta-Analysis; Piperazines; Postmenopause; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2 | 2020 |
[Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021].
Topics: Aged; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Clinical Trials as Topic; Female; Humans; Imidazoles; Immune Checkpoint Inhibitors; Letrozole; Leuprolide; Oxazepines; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Progression-Free Survival; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Selective Estrogen Receptor Modulators | 2022 |
4 trial(s) available for aromasil and palbociclib
| Article | Year |
|---|---|
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Topics: Aged; Anastrozole; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; DNA, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Middle Aged; Nitriles; Piperazines; Prospective Studies; Pyridines; Retrospective Studies; Triazoles | 2016 |
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Drug Therapy, Combination; Female; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Middle Aged; Neoplasm Metastasis; Piperazines; Prognosis; Pyridines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate | 2019 |
Mutation analysis using cell-free DNA for endocrine therapy in patients with HR+ metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Circulating Tumor DNA; DNA Mutational Analysis; Everolimus; Female; Humans; Letrozole; Middle Aged; Mutation; Neoplasm Proteins; Piperazines; Pyridines | 2021 |
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive metastatic breast cancer: Patient-reported outcomes in the PEARL study.
Topics: Androstadienes; Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Capecitabine; Disease Progression; Estrogen Receptor Antagonists; Europe; Female; Fulvestrant; Health Status; Humans; Israel; Neoplasm Metastasis; Patient Reported Outcome Measures; Piperazines; Postmenopause; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Quality of Life; Time Factors | 2021 |
5 other study(ies) available for aromasil and palbociclib
| Article | Year |
|---|---|
FGFR2 amplification in metastatic hormone-positive breast cancer and response to an mTOR inhibitor.
Topics: Adult; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gene Amplification; Goserelin; Humans; Piperazines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; TOR Serine-Threonine Kinases | 2017 |
Endocrine-based therapy versus chemotherapy in advanced breast cancer.
Topics: Androstadienes; Breast Neoplasms; Capecitabine; Female; Gonadotropin-Releasing Hormone; Humans; Piperazines; Pyridines | 2019 |
Severe Cellular Immunodeficiency Triggered by the CDK4/6 Inhibitor Palbociclib.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Fatal Outcome; Female; Humans; Immunocompromised Host; Lymphocyte Count; Lymphopenia; Piperazines; Pneumocystis; Pneumonia, Pneumocystis; Pyridines; Severity of Illness Index; Trimethoprim, Sulfamethoxazole Drug Combination | 2020 |
Lack of everolimus diffusion in pleural fluid during pleural progression of breast cancer: A case report.
Topics: Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Everolimus; Female; Humans; Piperazines; Pyridines | 2021 |
Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL).
Topics: Adult; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Female; Humans; Mastectomy; Middle Aged; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Piperazines; Progression-Free Survival; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2021 |